Ingersoll Rand Inc. · NYSE:IR
Ingersoll Rand — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
15 slides from Ingersoll Rand's conference presentation, Jan 14, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference January 14, 2026 Vicente Reynal, Chairman & CEO Vik Kini, SVP & CFO Scott Watson, SVP & GM, Life Science Technologies
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the expectations of Ingersoll Rand Inc. (the “Company” or “Ingersoll Rand”), regarding the performance of its
Slide 3: This is Ingersoll Rand today...
This is Ingersoll Rand today... A leading global provider of mission-critical flow and sustainable creation solutions with a 166-year history ~$7.5B ~$2.0B ~27% ~$1.3B ~$34.3B ~330% LTM Revenue1 LTM Adj. EBITDA1,4 LTM Adj. EBITDA LTM Free Cash Flow1,4 Market Cap2 Total Shareholder Return (Q3 2025) (
Slide 4: Product and technology leadership
Product and technology leadership Broad flow creation, industrial products, and life science solutions portfolio, with #1 or #2 market position in key categories Industrial Air/gas compressors Industrial vacuum Technologies and air treatment Blowers pumps and systems and Services Broad range of comp
Slide 5: Premier growth compounder with iconic brands and market leading positions
Remain nimble through our competitive differentiator, IRX 01 By leveraging Ingersoll Rand Execution Excellence (IRX) together with our unique Demand Generation approach, we expect to deliver above-market growth We are a Premier growth 02 Robust M&A funnel enabling future inorganic growth In 2025, 16
Slide 6: IRX and our ownership mindset drive our performance
IRX and our ownership mindset drive our performance Ingersoll Rand Execution Excellence (IRX) Employee ownership philosophy We have completed multiple all-employee equity grants since the IPO of Gardner Denver in 2017 As part of our Ownership Works program, 100% of all new employees are eligible to
Slide 7: This has led to an outperformance in the market; ~$30B value creation
This has led to an outperformance in the market; ~$30B value creation April 2019 IR and GD March 2024 March 2023 Announce Announced Purchase Received Merger April 2021 of ILC Dover Upgrade to Announced Sale Investment Since 2017 IPO1 of Club Car Grade (BBB-) October 2022 From S&P April 2025 Announce
Slide 8: We continue to shift the portfolio to high-growth, sustainable markets
We continue to shift the portfolio to high-growth, sustainable markets; with more runway ahead 2020 Estimated revenue by end market1 2024 Estimated revenue by end market1 Life Sciences 18% General Manufacturing 28% Other Other Clean 46% 46% Energy 12% Specialty Vehicles 12% 13% Food and Beverage 9%
Slide 9: Life Science Technologies
Life Science Technologies CED ingerson rand.
Slide 10: Ingersoll Rand Life Science Technologies businesses and commercial brands
Ingersoll Rand Life Science Technologies businesses and commercial brands Flow Control Solutions Biopharma & Pharma Solutions Medical Device Solutions Pumps and other components in highly Material handling and containment in biopharma Contract medical device manufacturing engineered OEM applications
Slide 11: High quality businesses positioned across multiple growing value chains
High quality businesses positioned across multiple growing value chains Diverse market segments, long- Strong mix of high-value consumables, Active presence in hotbeds of term secular tailwinds critical to customers’ applications investment and production activity Equipment. & Non- Recurring Enginee
Slide 12: A platform for accretive bolt-on M&A
A platform for accretive bolt-on M&A ILC Dover, acquired in 2024, has become a beachhead for additional acquisitions with attractive market applications across Life Sciences Acquisition Target market fit Core M&A characteristics and criteria ▪ Exposure to downstream bioprocessing liquid handling ▪ E
Slide 13: Commercial synergies pulling through the broader Ingersoll Rand portfolio
Commercial synergies pulling through the broader Ingersoll Rand portfolio Ingersoll Rand’s portfolio applied in small molecule API production workflows 1 2 Material Prep & Control Chemical Synthesis Plant Utilities Clean-room Trolley: Single Use Isolator: Air Operated Double Jet Mixer: Chiller: Prec
Slide 14: Unique solutions that create value for customers in applications with strong growth drivers
Unique solutions that create value for customers in applications with strong growth drivers Application: Antibody drug conjugates Application Products Why We Win • Antibody drug conjugates • Single-use isolators systems Technology leadership (ADCs) are novel therapies for • Single-use powder bags an
Slide 15: Key Takeaways
~$30B Shareholder Value Creation Continuing to differentiate in ~8 years Ingersoll Rand as an investment: ▪ ~$7.5B Revenue diversified Life ▪ Proven track record of Science and Industrial Solutions agility and performance delivering compounder playing in a ~$65B double digit Adj. Diluted EPS CAGR1 a
Ingersoll Rand — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix